Clinical Trial

JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia

Recruiting
View on ClinicalTrials.gov →
Summary
This study is an investigator-initiated single center, single arm clinical study with a target population of patients with relapsed or refractory B cell lymphoma /leukemia. It is an early exploratory clinical study of the safety, tolerability and initial efficacy of JY231 injection in the treatment of relapsed or refractory B cell lymphoma / leukemia.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-16.
Status change: Not Yet Recruiting → Recruiting 2025-05-12
Trial Details
NCT Number NCT06890065
Lead Sponsor Shenzhen Genocury Biotech Co., Ltd.
Conditions B Acute Lymphoblastic Leukemia, B-Non Hodgkin Lymphoma
Enrollment 20 participants
Start Date 2025-03-01
Primary Completion 2027-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2025-05-15